John McMannis

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.

MedXCell SA is a European cell therapy venture builder that focuses on identifying scientific breakthroughs and transforming them into clinical assets. The private company is based in Montreux, Switzerland. The Swiss company has a strong industrial mindset and a multidisciplinary expert team with entrepreneurial, clinical, operational, business development, and funding capabilities. MedXCell scouts for promising ideas within its European academic network of partners, selects the most commercially-viable ideas, and co-develops them with academic institutions until the proof-of-principle stage. The company creates pipeline companies based on those ideas that can be funded independently and monetizes those that can be sold or out-licensed as early-stage assets. MedXCell was founded in 2016 by Laurent Zbinden, who has been the CEO since then.